DR Owens, B Zinman, GB Bolli - The Lancet, 2001 - Elsevier The advent of insulin almost 80 years ago revolutionised treatment of diabetes
and must be one of the most outstanding achievements of twentieth century
medicine. Since then, there has been an ever-increasing awareness and ... Cited by 192 - Related articles - BL Direct - All 5 versions
M Takenaga, Y Yamaguchi, A Kitagawa, Y … - Journal of Controlled Release, 2002 - Elsevier To ensure a strictly controlled release of insulin, a preparation method for
insulin-loaded microcapsules was designed. Microcapsules were prepared with an
injectable, biodegradable polymer composed of co-poly( , -lactic/glycolic) ... Cited by 41 - Related articles - All 7 versions
- ►jbc.org H Tsubery, M Mironchik, M Fridkin, Y Shechter - Journal of Biological Chemistry, 2004 - ASBMB Polyethylene glycol (PEG)-conjugated therapeutic peptides/proteins have been
shown to exhibit clinical properties superior to those of their corresponding
unmodified parent molecules. However, the desirable pharmacological ... Cited by 23 - Related articles - BL Direct - All 4 versions
S Lee, K Kim, TS Kumar, J Lee, SK Kim, DY … - Bioconjugate chemistry, 2005 - matlb.kjist.ac.kr Bile acids have been considered very useful in the preparation of new
pharmaceuticals, and more recently in the preparation of peptide and protein
drugs because of their natural chemical and biological properties. In this ... Cited by 17 - Related articles - View as HTML - All 6 versions
Y Shechter, I Goldwaser, I Lavon, E Gershonov … - Drugs of the Future, 2001 - journals.prous.com Most peptide and protein drugs are short-lived species in vivo, having a
circulatory half-life of several minutes. This is particularly valid for
nonglycosylated proteins of a molecular mass less than 50,000 daltons. The ... Cited by 9 - Related articles - All 2 versions
M Sato, R Sadamoto, K Niikura, K Monde, H … - ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN …, 2004 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 9 - Related articles - BL Direct - All 4 versions
M Takenaga, Y Yamaguchi, A Kitagawa, Y … - Journal of Pharmacy and Pharmacology, 2002 - ingentaconnect.com We have recently succeeded in preparing insulin-loaded microcapsules that
release the insulin in a strictly controlled manner with little initial rapid
release in-vitro or in-vivo. We show here the superiority of the best ... Cited by 7 - Related articles - BL Direct - All 3 versions
G Fridkin, C Gilon, T Gilon, A Loyter - Journal of Peptide Research, 2001 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 6 - Related articles - BL Direct - All 4 versions
Y Shechter, H Tsubery, M Fridkin - Biochemical and Biophysical Research …, 2003 - Elsevier Exendin-4, a glucagon-like peptide-1 agonist, is a relatively short-lived
species in the circulatory system in vivo. We have linked three moieties of
2-sulfo-9-fluorenylmethoxycarbonyl (FMS) to the three amino functions of ... Cited by 3 - Related articles - BL Direct - All 3 versions
Y Shechter, H Tsubery, M Fridkin - Biochemical and Biophysical Research …, 2003 - Elsevier FMS 3 –insulin (2-sulfo-9-fluorenylmethoxycarbonyl) 3 –insulin is a water
soluble, inactive-reactivated derivative of insulin with protracted action in
vivo. In this study we find that FMS 3 –insulin preserves insulin's ... Cited by 3 - Related articles - All 5 versions
